Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23
News > Health News
Audio By Carbonatix
1:00 PM on Wednesday, October 22
The Associated Press
FREMONT, Calif.--(BUSINESS WIRE)--Oct 22, 2025--
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine.
When: | Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT | |
Panel Title: | Building a Big Tent | |
Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community, engage first movers, foster cross-sector collaboration, and bring payors and pharma to the table as allies in driving adoption and impact. | ||
Panelists: | Scott Gottlieb, MD, Former Commissioner, FDA; Partner, New Enterprise Associates | |
Jennifer Ernst, Founder and CEO – Tivic Health | ||
John M. O’Brien, PharmD, President and CEO, National Pharmaceutical Council | ||
Moderator: Allysia Finley, Editorial Board Member and Life Science Columnist, The Wall Street Journal |
About the Northwell Health Innovation Summit and Constellation Forum
For nearly a decade, the Constellation Forum has become a premier industry event for Fortune 500 executives, healthcare luminaries, public and private investors, leading philanthropists, scientific pioneers, and top entrepreneurs. Participants engage around one simple yet audacious goal – to catalyze inspired partnerships that are powering the future of health.
The 2025 program will focus on bioelectronic medicine — a transformative frontier where science, technology, and patient care converge. This new field of medicine, which uses device technology to modulate the body’s nervous system, is at a tipping point. Our world-class speakers and distinguished guests will gather to illuminate the breakthroughs and success stories, explore commercialization and investment strategies, and tackle the key challenges that must be overcome to scale bioelectronic medicine into everyday care.
About Tivic Health Systems, Inc.
Tivic’s dual platform utilizes the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic’s biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company’s lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designations and is in late-stage development. Tivic’s bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic’s approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: https://ir.tivichealth.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading "Risk Factors", as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251022353037/en/
CONTACT: Investor Contact:
Hanover International, Inc.
ir@tivichealth.comMedia Contact:
Deanne Eagle or Laura Min Jackson
media@tivichealth.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY ENTREPRENEUR HEALTH RADIOLOGY PHARMACEUTICAL HEALTH TECHNOLOGY MEDICAL DEVICES RESEARCH CONSUMER SCIENCE CLINICAL TRIALS
SOURCE: Tivic Health Systems, Inc.
Copyright Business Wire 2025.
PUB: 10/22/2025 02:00 PM/DISC: 10/22/2025 01:59 PM
http://www.businesswire.com/news/home/20251022353037/en
